Fluidigm and Life Technologies Cross-License a Broad Set of Intellectual Properties
News Jul 12, 2011
Under the terms of the agreements, Fluidigm will gain broad access to patent families covering PCR related technologies of Life Technologies. In addition, Life Technologies will gain broad access to a number of Fluidigm patent families related to imaging readers and other technologies.
Recent legal actions that had been filed by both parties have been withdrawn.
“This is a very positive outcome for both companies. It provides each company with the freedom to compete in the marketplace instead of the courtroom,” said Gajus Worthington, Fluidigm President and Chief Executive Officer. “We are pleased to have broad access to the PCR patent portfolio of Life Technologies. This ensures that our customers have access to a broad array of assays on our advanced systems, such as our BioMark™ HD. We are also pleased to have the first recognition of the value of our non-core IP (intellectual property), which builds significant value for others outside of our core platform.”